Scholarlink

Antimicrobial resistance has become an urgent public health problem, thus new antibiotics and antimicrobial strategies have been widely studied to circumvent this problem. Our objective is to test the bacteriocin BRE349, the one partially purified from the endophytic strain Bacillus amyloliquefaciens BE349, against strains of Methicillin-Resistant Staphylococcus aureus (MRSA) isolated from a hospital environment, and evaluate its potential to prevent biofilm formation. BRE349 was partially purified with 80% ammonium sulfate saline saturation, then lyophilized and concentrated. The resistance to physicochemical and proteolytic stresses, the minimum inhibitory concentration, the minimum bactericidal concentration, the biofilm formation inhibition activity, and the killing kinetics against clinical isolates of MRSA were determined. BRE349 presented 10,240 AU/ml of activity and a moderately resistant profile to temperature and pH variation; MIC ranged from 62.5 to 500 µg/ml. All concentrations strongly inhibited biofilm formation against all tested strains. BRE349 showed a bactericidal profile after 4 h of cultivation at a concentration of 1 × MIC, and a bacteriostatic profile at 1/2 MIC concentration. BRE349 is a strong protein molecule candidate for use in the prophylaxis of nosocomial infections caused by MRSA, thus it can be depicted in biotechnological applications due to its high capacity to inhibit biofilm formation.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization and Partial Purification of Bacteriocin Produced by Bacillus amyloliquefaciens BE349: Biological Activities Against MRSA Clinical Isolates

  • 章节

  • 发表日期：

    2026年

查看全文
  • Diego S. C. Marques,
  • Elba V. M. Maciel de Carvalho,
  • Natalie E. R. Rodrigues,
  • Priscilla B. S. de Albuquerque,
  • Leonor A. O. Silva,
  • Gláucia M. S. Lima,
  • Luana C. B. B. Coelho

摘要

Antimicrobial resistance has become an urgent public health problem, thus new antibiotics and antimicrobial strategies have been widely studied to circumvent this problem. Our objective is to test the bacteriocin BRE349, the one partially purified from the endophytic strain Bacillus amyloliquefaciens BE349, against strains of Methicillin-Resistant Staphylococcus aureus (MRSA) isolated from a hospital environment, and evaluate its potential to prevent biofilm formation. BRE349 was partially purified with 80% ammonium sulfate saline saturation, then lyophilized and concentrated. The resistance to physicochemical and proteolytic stresses, the minimum inhibitory concentration, the minimum bactericidal concentration, the biofilm formation inhibition activity, and the killing kinetics against clinical isolates of MRSA were determined. BRE349 presented 10,240 AU/ml of activity and a moderately resistant profile to temperature and pH variation; MIC ranged from 62.5 to 500 µg/ml. All concentrations strongly inhibited biofilm formation against all tested strains. BRE349 showed a bactericidal profile after 4 h of cultivation at a concentration of 1 × MIC, and a bacteriostatic profile at 1/2 MIC concentration. BRE349 is a strong protein molecule candidate for use in the prophylaxis of nosocomial infections caused by MRSA, thus it can be depicted in biotechnological applications due to its high capacity to inhibit biofilm formation.